A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease

Movement Disorders

Volumn 30, Issue 2, 2015, Pages 288-289

  Prundean, Adriana ^a   Youssov, Katia ^b,c,d   Humbert, Sandrine ^e   Bonneau, Dominique ^a,c   Verny, Christophe ^a,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d ECOLE NORMALE SUPÉRIEURE   (France)

^e INSERM U1005   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTAMINE;

ADULT; AGED; ARTHRALGIA; ASTHENIA; BALANCE DISORDER; BODY WEIGHT DISORDER; CAG REPEAT; CLINICAL ARTICLE; CONJUNCTIVITIS; DAILY LIFE ACTIVITY; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPISTAXIS; ERUCTATION; FATIGUE; FEMALE; FEVER; FLATULENCE; GASTROESOPHAGEAL REFLUX; HAIR LOSS; HALITOSIS; HERPES SIMPLEX; HERPETIC STOMATITIS; HUMAN; HUNTINGTON CHOREA; INFECTION; LEG PAIN; LETTER; LEUKOCYTOSIS; LIMB PAIN; MALE; MIGRAINE; MOTOR DYSFUNCTION; MOUTH PAIN; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RHINORRHEA; SIDE EFFECT; SKIN ODOR; SLEEP DISORDER; UNIFIED HUNTINGTON DISEASE RATING SCALE; WEIGHT REDUCTION; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; DRUG TOLERANCE; HUNTINGTON DISEASE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; CYSTEAMINE; DRUG TOLERANCE; HUMANS; HUNTINGTON DISEASE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922262761     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26101     Document Type: Letter

References (7)

1. Wang X, Sarkar A, Cicchetti F, et al. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 2005;231:57-66.
2. Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem. 2005;95:210-220.
3. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002;8:143-149.
4. Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 2002;22:8942-8950.
5. Cherqui S. Cysteamine therapy: a treatment for cystinosis, not a cure. Kidney Int 2012;81:127-129.
6. Shults C, Steardo L, Barone P, et al. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology 1986;36:1099-1102.
7. Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 2006;21:530-533.